Italian hospitals track Real-World results of lung cancer immunotherapy

This study is collecting information from about 400 patients in Italy who are already receiving a specific two-drug immunotherapy combination (nivolumab plus ipilimumab) as their first treatment for advanced or returning non-small cell lung cancer. The goal is to understand how well the treatment works, how safe it is, and what patients' experiences are like in everyday hospital practice, rather than in a controlled trial. Researchers will track survival, quality of life, and side effects to build a clearer picture of real-world outcomes.